



For Immediate Release

RoverMed BioSciences Raises Over-Subscribed Angel Round

Minnesota Gopher Angels Lead a More Than \$1 Million Fundraising Round

Minneapolis, MN (08/24/17) – St. Cloud-based bioscience startup RoverMed BioSciences oversubscribed their initial \$500,000 angel round offering by over \$500,000, totaling more than \$1 million in new investment. Gopher Angels, a Minnesota-based angel investor network, led the round. Other participants included St. Louis-based Arch Angels, North Dakota-based 701 Angel Fund, multiple individual investors and a strategic biotech investor.

"The team at RoverMed is energized to have successfully oversubscribed this angel round from investors here in Minnesota as well as across the country," said Laura Brod, CEO of RoverMed. "We believe it is a ringing vote of confidence in our strategy and technology that was invented through years of hard work and research by our top-notch CSO, Dr. Gretchen Unger, and her team."

According to Gopher Angels Executive Director Chris Reedy, "We believe RoverMed's new platform technology for delivering drugs can solve fundamental problems with emerging and existing therapies. We are so proud to have led a strong group of financial and strategic investors nationally who share our excitement about RoverMed's team and technology."

"We are seeing a lot of traction in our young company. And, having a strategic industry investor participate in this early round is beyond encouraging," concluded Brod. "There is a clear and present need for our novel drug delivery system in the market and we will have a laser focus on working seamlessly with our pharma and biotech partners to fill that need."

And, in highlighting a unique aspect of RoverMed's team, Sara Russick, Gopher Angels founder & managing director, stated, "It's exciting to support this high quality company that's led by 2 amazing women, CEO Laura Brod and CSO Dr. Gretchen Unger. Gopher Angels is confident that they'll drive value for this company."

Use of proceeds from this round will be used to advance RoverMed's novel drug delivery system on its path to commercialization. Investments will include increased spending on intellectual property portfolio expansion, scale-up activities, and additions to their scientific and business development teams to support their engagement with potential pharmaceutical partners.

About RoverMed BioSciences

RoverMed's Crystalline Ultra-Small Particle (CUSP) is the leading nanocapsule technology capable of cell specific delivery of biologic drugs directly to the nucleus of disease cells to deliver precision-targeted treatments for challenging diseases. RoverMed's technology carries medication beyond the human liver – which thwarts many therapeutic delivery



advances – and exclusively into the nuclei of targeted cells, no matter where those cells are located in the body. The company’s technology is designed to achieve unequalled delivery efficiency, precision targeting, and effectiveness.

Media Contact: Jing Zhang
Media Email: jing@ainsleyshea.com
Media Phone: 651-414-1095